Neuronal forms of gaucher disease

Handbook of Experimental Pharmacology

Volumn 216, Issue , 2013, Pages 405-419

  Vitner, Einat B ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Gaucher disease; Glucosylceramidase; Glucosylceramide; Neurodegeneration

Indexed keywords

CALCIUM ION; CATHEPSIN D; GALACTOSYLCERAMIDASE; GALACTOSYLCERAMIDE; GLUCOSYLCERAMIDE;

ARTICLE; BIOCHEMISTRY; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MODEL; DOPAMINERGIC ACTIVITY; ENZYME MODIFICATION; ENZYME REPLACEMENT; EXPERIMENTAL MOUSE; GAUCHER DISEASE; HUMAN; MOLECULAR PATHOLOGY; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRESYNAPTIC NERVE; PRIORITY JOURNAL; ANIMAL; BRAIN; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOUSE; NERVE CELL; PATHOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSYLCERAMIDES; HUMANS; MICE; NEURONS; PARKINSON DISEASE; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84880537720     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-7091-1511-4_20     Document Type: Article

References (82)

1. Alonso-Canovas A, Katschnig P, Tucci A, Carecchio M, Wood NW, Edwards M et al (2010) Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: case report and literature review. Mov Disord 25(10):1506-1509
2. Azuri J, Elstein D, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A (1998) Asymptomatic Gaucher disease implications for large-scale screening. Genet Test 2(4):297-299
3. Balducci C, Pierguidi L, Persichetti E, Parnetti L, Sbaragli M, Tassi C et al (2007) Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov Disord 22(10):1481-1484
4. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A et al (1999) Cytokines in Gaucher's disease. Eur Cytokine Netw 10(2):205-210
5. Berg D, Roggendorf W, Schroder U, Klein R, Tatschner T, Benz P et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59(6):999-1005
6. Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35(3):355-364
7. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE (2008) 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 31(3):337-349
8. Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I et al (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid betaglucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282(39):29052-29058
9. Capablo JL, Saenz de Cabezon A, Fraile J, Alfonso P, Pocovi M, Giraldo P (2008) Neurological evaluation of patients with Gaucher disease diagnosed as type 1. J Neurol Neurosurg Psychiatry 79(2):219-222
10. Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A (1984) Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol 65(2):99-109
11. Conradi NG, Kalimo H, Sourander P (1988) Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease. Acta Neuropathol 75(4):385-390
12. Conradi N, Kyllerman M, Mansson JE, Percy AK, Svennerholm L (1991) Late-infantile Gaucher disease in a child with myoclonus and bulbar signs: neuropathological and neurochemical findings. Acta Neuropathol 82(2):152-157
13. Cox TM, Schofield JP (1997) Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 10(4):657-689
14. Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ et al (2011) Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann Neurol 69(6):940-953
15. Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH et al (2003) X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 4(7):704-709
16. Eblan MJ, Nguyen J, Ziegler SG, Lwin A, Hanson M, Gallardo M et al (2006) Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Mov Disord 21(2):282-283
17. Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M et al (2007) Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA 104(44):17483-17488
18. Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S et al (2009) No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet 18(8):1482-1488
19. Farfel-Becker T, Vitner EB, Futerman AH (2011a) Animal models for Gaucher disease research. Dis Model Mech 4(6):746-752
20. Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH (2011b) Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet 20(7):1375-1386
21. Fill M, Copello JA (2002) Ryanodine receptor calcium release channels. Physiol Rev 82(4):893-922
22. Futerman AH, Pagano RE (1991) Determination of the intracellular sites and topology of glucosylceramide synthesis in rat liver. Biochem J 280(Pt 2):295-302
23. Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A (2004) New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 25(3):147-151
24. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70(24):2277-2283
25. Gaucher PCE (1882) De l'Epithélioma Primitif de la Rate: Hypertrophie Idiopathique de la Rate sans Leucémie, Ph.D. Thesis. University of Paris, Paris
26. Gault CR, Obeid LM, Hannun YA (2010) An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol 688:1-23
27. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E (2004) Parkinsonism among Gaucher disease carriers. J Med Genet 41(12):937-940
28. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65(10):1353-1357
29. Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E (2010) Glucocerebrosidase is present in alpha-synuclein inclusions in Lewy body disorders. Acta Neuropathol 120(5):641-649
30. Halperin A, Elstein D, Zimran A (2006) Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 36(3):426-428
31. Henkart M (1980) Identification and function of intracellular calcium stores in neurons. Fed Proc 39(10):2776-2777
32. Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23(2):201-212
33. Hong YB, Kim EY, Jung SC (2006) Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J Korean Med Sci 21(4):733-738
34. Horowitz M, Zimran A (1994) Mutations causing Gaucher disease. Hum Mutat 3(1):1-11
35. Jmoudiak M, Futerman AH (2005) Gaucher disease: pathological mechanisms and modern management. Br J Haematol 129(2):178-188
36. Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 452(2):87-89
37. Kanfer JN, Legler G, Sullivan J, Raghavan SS, Mumford RA (1975) The Gaucher mouse. Biochem Biophys Res Commun 67(1):85-90
38. Kaye EM, Ullman MD, Wilson ER, Barranger JA (1986) Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann Neurol 20(2):223-230
39. Kinghorn KJ (2011) Pathological looping in the synucleinopathies: investigating the link between Parkinson's disease and Gaucher disease. Dis Model Mech 4(6):713-715
40. Kono S, Ouchi Y, Terada T, Ida H, Suzuki M, Miyajima H (2010) Functional brain imaging in glucocerebrosidase mutation carriers with and without parkinsonism. Mov Disord 25(12):1823-1829
41. Korkotian E, Schwarz A, Pelled D, Schwarzmann G, Segal M, Futerman AH (1999) Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 274(31):21673-21678
42. Legler G, Bieberich E (1988) Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F. Arch Biochem Biophys 260(1):437-442
43. Lloyd-Evans E, Pelled D, Riebeling C, Bodennec J, de-Morgan A, Waller H et al (2003) Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 278(26):23594-23599
44. Manning-Bog AB, Schule B, Langston JW (2009) Alpha-synuclein- glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30(6):1127-1132
45. Mao XY, Burgunder JM, Zhang ZJ, An XK, Zhang JH, Yang Y et al (2010) Association between GBA L444P mutation and sporadic Parkinson's disease from Mainland China. Neurosci Lett 469(2):256-259
46. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA et al (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37-52
47. Merrill AH Jr (2011) Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-6422
48. Mikoshiba K (1997) The InsP3 receptor and intracellular Ca2φ signaling. Curr Opin Neurobiol 7(3):339-345
49. Mizukami H, Mi Y, Wada R, Kono M, Yamashita T, Liu Y et al (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 109 (9):1215-1221
50. Offman MN, Krol M, Silman I, Sussman JL, Futerman AH (2010) Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370S. J Biol Chem 285(53):42105-42114
51. Pastores GM, Barnett NL, Bathan P, Kolodny EH (2003) A neurological symptom survey of patients with type I Gaucher disease. J Inherit Metab Dis 26(7):641-645
52. Pelled D, Shogomori H, Futerman AH (2000) The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inherit Metab Dis 23 (2):175-184
53. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH (2005) Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 18(1):83-88
54. Platt FM, Jeyakumar M (2008) Substrate reduction therapy. Acta Paediatr Suppl 97(457):88-93
55. Platt FM, Lachmann RH (2009) Treating lysosomal storage disorders: current practice and future prospects. Biochim Biophys Acta 1793(4):737-745
56. Poupetova H, Ledvinova J, Berna L, Dvorakova L, Kozich V, Elleder M (2010) The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 33(4):387-396
57. Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, Kelly JW et al (2005) X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem 280(25):23815-23819
58. Rogaeva E, Hardy J (2008) Gaucher and Parkinson diseases: unexpectedly related. Neurology 70(24):2272-2273
59. Saunders-Pullman R, Hagenah J, Dhawan V, Stanley K, Pastores G, Sathe S et al (2010) Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 25(10):1364-1372
60. Sawkar AR, D'Haeze W, Kelly JW (2006) Therapeutic strategies to ameliorate lysosomal storage disorders-A focus on Gaucher disease. Cell Mol Life Sci 63(10):1179-1192
61. Schiffmann R, Vellodi A (2007) Neuoronopathic Gaucher disease. In: Futerman AH, Zimran A (eds) Gaucher disease. CRC, Boca Raton, pp 175-196
62. Shachar T, Lo Bianco C, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH (2011) Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 26(9):1593-1604
63. Sidransky E, Fartasch M, Lee RE, Metlay LA, Abella S, Zimran A et al (1996) Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res 39(1):134-141
64. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361(17):1651-1661
65. Stephens MC, Bernatsky A, Burachinsky V, Legler G, Kanfer JN (1978) The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects. J Neurochem 30 (5):1023-1027
66. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV et al (2010) Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19(6):1088-1097
67. Sun Y, Ran H, Liou B, Quinn B, Zamzow M, Zhang W et al (2011) Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS One 6(4):e19037
68. Suzuki K (2003) Globoid cell leukodystrophy (Krabbe's disease): update. J Child Neurol 18(9):595-603
69. Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79(2):104-109
70. Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, Winfield S et al (1992) Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357(6377):407-410
71. Velayati A, Yu WH, Sidransky E (2010) The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 10(3):190-198
72. Vellodi A, Tylki-Szymanska A, Davies EH, Kolodny E, Bembi B, Collin-Histed T et al (2009) Management of neuronopathic Gaucher disease: revised recommendations. J Inherit Metab Dis 32(5):660-664
73. Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R et al (2010a) Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Hum Mol Genet 19(18):3583-3590
74. Vitner EB, Platt FM, Futerman AH (2010b) Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 285(27):20423-20427
75. Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH (2012) Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher disease. Brain 135:1724-1735
76. Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB (2008) ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and nonneurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet 17(4):469-477
77. Wei RR, Hughes H, Boucher S, Bird JJ, Guziewicz N, Van Patten SM et al (2011) X-ray and biochemical analysis of N370S mutant human acid beta-glucosidase. J Biol Chem 286 (1):299-308
78. Willemsen R, Tybulewicz V, Sidransky E, Eliason WK, Martin BM, LaMarca ME et al (1995) A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol Chem Neuropathol 24(2-3):179-192
79. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK et al (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82(3):192-207
80. Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA (2011) Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102(4):436-447
81. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N et al (2011) Alphasynuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 286(32):28080-28088
82. Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, Goker-Alpan O et al (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91(2):195-200